CA
RAPP

Clearstead Advisors’s Rapport Therapeutics RAPP Stock Holding History

Clearstead Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33
Closed -$981 – 3313
2025
Q3 		$981 Buy
+33
New +$589 ﹤0.01% 2621

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Clearstead Advisors's RAPP Position: Q4 2025 in Review

Clearstead Advisors sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 33 shares — an estimated $981 sold.

Clearstead Advisors first reported a position in RAPP in Q3 2025 and held it in 1 quarter. The position peaked at $981 in Q3 2025. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Clearstead Advisors reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 33 Rapport Therapeutics shares in Q4 2025, an estimated $981.
  • Clearstead Advisors first reported a position in Rapport Therapeutics in Q3 2025 and held it in 1 quarter.
  • Clearstead Advisors's Rapport Therapeutics position peaked at $981 in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.